Aspirin and new antiplatelet drugs are both used for the prevention and treatment of cardiovascular diseases, but they have some key differences.

First, aspirin is an non-steroidal anti-inflammatory drug (NSAID) that has been in use for over a century, while new antiplatelet drugs, such as ticagrelor and prasugrel, are relatively new to the market.

Second, aspirin works by irreversibly inhibiting the cyclooxygenase-1 (COX-1) enzyme, which prevents the formation of thromboxane A2 and ultimately inhibits platelet aggregation. In contrast, new antiplatelet drugs, such as ticagrelor and prasugrel, are P2Y12 receptor antagonists that reversibly bind to the P2Y12 receptor on platelets, preventing adenosine diphosphate (ADP) from activating the platelet and thus inhibiting platelet aggregation.

Third, aspirin has a long half-life and its effects persist for the lifespan of the platelets, while new antiplatelet drugs have a shorter half-life and their effects wear off more quickly.

Fourth, aspirin is available over-the-counter in many countries and is relatively inexpensive, while new antiplatelet drugs are prescription-only and can be expensive.

Fifth, aspirin is associated with a higher risk of gastrointestinal bleeding compared to new antiplatelet drugs.

In summary, while aspirin and new antiplatelet drugs both inhibit platelet aggregation, they have different mechanisms of action, half-lives, availability, and side effect profiles.

Sources:

* <https://www.drugpatentwatch.com/p/tradename/ASPIRIN>
* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602973/>
* <https://www.nejm.org/doi/full/10.1056/NEJMoa1712746>